Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: A pilot study

Maturitas

Volumn 36, Issue 1, 2000, Pages 63-68

  Wildemeersch, D ^a   Schacht, E ^b  

^a Gynecological Outpatient Clinic and IUD Training Center   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Contraception; Hormone substitution therapy; Intrauterine drug delivery system (IUS); Levonorgestrel

Indexed keywords

ESTRADIOL; LEVONORGESTREL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

ADULT; DRUG DELIVERY SYSTEMS; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENOPAUSE; MIDDLE AGED; PILOT PROJECTS; PROGESTERONE CONGENERS;

EID: 0034738374     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00136-5     Document Type: Article

References (12)

1. Sarrel P.M. Progestogens and blood flow. Int. Proc. J. 1:1991;266-271.
2. Miller V., Muesing R.A., LaRosa J.C., Stoy D.P., Phillips E.A., Stillman R.J. Effects of conjugated equine estrogens with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions and apolipoprotein A1. Obstet. Gynecol. 77:1991;235-240.
3. Adams M.R., Kaplan J.R., Manuck S.B. et al. Inhibition of coronary artery artherosclerosis by 17-beta estradiol in ovarectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 10:1990;1051-1057.
4. Haaro J., Leth-Espensen P., Stender S., Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovarectomized cholesterol-fed rabbits. J. Clin. Invest. 87:1991;1274-1279.
5. Furchgott R.F., Zawadski J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acethylcholine. Nature. 288:1980;373-376.
6. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. Vittinghoff E for the heart and estrogen/progestin replacement study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;605-613.
7. Sarrel PM, Albakri E. et al. Oral progesterone therapy impairs cerebrovascular reactivity. American Heart Association 20th International Joint Conference on Stroke and Cerebral Circulation, February, Charleston, SC, 1995.
8. Henderson B.E., Paganini-Hill A., Ross R.K. Estrogen replacement therapy and protection from acute myocardial infarction. Am. J. Obstset. Gynecol. 159:1988;312-317.
9. Wildemeersch D., Batar I., Webb A., Gbolade B.A., Delbarge W., Temmerman M., Dhont M., Guillebaud J. GyneFIX®. The frameless intrauterine contraceptive implant implant for interval, emergency and postabortal contraception - an update. Br. J. Fam. Plann. 24:1999;149-159.
10. Boon J. The LNG intrauterine system as part of continuous combined HRT in perimenopausal women. Dissertation, University Utrecht, Faculty of Medicine, The Netherlands, 1998.
11. Fleischer AC, Kepple DM. Benign conditions of the uterus, cervix and endometrium. In: Nyberg DA, Hill LM, Böhm-Velez M, Mendelson EB editors, Transvaginal ultrasound. Mosby Year Book, St Louis, 1992, pp. 21-24.
12. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf. 15(6):1996;430-440.